评估尿N-乙酰-β-D-氨基葡萄糖苷酶作为2型糖尿病患者早期肾损伤标志物的作用。
Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus.
作者信息
Bouvet Beatriz R, Paparella Cecilia V, Arriaga Sandra M M, Monje Adriana L, Amarilla Ana M, Almará Adriana M
机构信息
Clinical Biochemistry Department, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina.
Nephrology Service, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina.
出版信息
Arq Bras Endocrinol Metabol. 2014 Nov;58(8):798-801. doi: 10.1590/0004-2730000003010. Epub 2014 Nov 1.
OBJECTIVE
To evaluate the clinical usefulness of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion for the detection of early tubular damage in type 2 diabetes mellitus (T2DM).
SUBJECTS AND METHODS
Thirty six patients with T2DM were divided into two groups based on urinary albumin to creatinine ratio (ACR): normoalbuminuria (ACR <30 mg/g; n=19) and microalbuminuria (ACR =30-300 mg/g; n=17). The following parameters were determined in both groups: urinary NAG and albumin, serum and urine creatinine, fasting plasma glucose and glycated hemoglobin (HbA1c).
RESULTS
Urinary NAG levels [Units/g creatinine; median (range)] were significantly increased in microalbuminuria group [17.0 (5.9 - 23.3)] compared to normoalbuminuria group [4.4 (1.5 - 9.2)] (P<0.001). No differences between groups were observed in fasting glucose, HbA1c, serum creatinine levels and estimated glomerular filtration rates (eGFR). Urinary NAG positively correlated with ACR (r=0.628; p<0.0001), while no significant association was observed between NAG and glycemia, HbA1c, serum creatinine and eGFR.
CONCLUSIONS
The increase of urinary NAG at the microalbuminuria stage of diabetic nephropathy (DN) suggests that tubular dysfunction is already present in this period. The significant positive association between urinary NAG excretion and ACR indicates the possible clinical application of urinary NAG as a complementary marker for early detection of DN in T2DM.
目的
评估尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)排泄量在2型糖尿病(T2DM)早期肾小管损伤检测中的临床应用价值。
对象与方法
36例T2DM患者根据尿白蛋白与肌酐比值(ACR)分为两组:正常白蛋白尿组(ACR<30mg/g;n=19)和微量白蛋白尿组(ACR=30-300mg/g;n=17)。两组均测定以下参数:尿NAG和白蛋白、血清及尿肌酐、空腹血糖和糖化血红蛋白(HbA1c)。
结果
微量白蛋白尿组尿NAG水平[单位/g肌酐;中位数(范围)]为17.0(5.9-23.3),显著高于正常白蛋白尿组的4.4(1.5-9.2)(P<0.001)。两组在空腹血糖、HbA1c、血清肌酐水平和估计肾小球滤过率(eGFR)方面未观察到差异。尿NAG与ACR呈正相关(r=0.628;p<0.0001),而NAG与血糖、HbA1c、血清肌酐和eGFR之间未观察到显著关联。
结论
糖尿病肾病(DN)微量白蛋白尿阶段尿NAG升高表明此期已存在肾小管功能障碍。尿NAG排泄量与ACR之间的显著正相关表明尿NAG可能作为T2DM中DN早期检测的补充标志物具有临床应用价值。